Severe Acute Respiratory Syndrome CoV 2 COVID-19 Survey and Vaccination Coverage in the Sickle Cell Population in Ile-De-France (COVIDO-DREP)

This is an interventional other trial for Sickle Cell Disease focused on measuring seroprevalence, SARS-CoV-2, sickle cell Read More

Inclusion Criteria:

• Patient group = children with sickle cell disease:
• Children over 12 months of age and under 18 at the time of inclusion.
• Children with a major sickle cell syndrome (SS, "C gene and one sickle hemoglobin (S) gene", Sβ+, Sβ°, SE) followed in one of the centers of competence or reference for rare diseases (CRMR) "Major Sickle Cell Syndromes, Thalassemias and Other Rare Pathologies of Red Blood Cell and Erythropoiesis "from Ile de France.
• Children not subject to legal protection measures.
• Children affiliated to a French social security scheme
• Informed consent signed by one of the two parents.

Group of adults with sickle cell disease:

• Patients over 18 years of age at the time of inclusion (male, female).
• Patients with a major sickle cell syndrome (SS, "C gene and one sickle hemoglobin (S) gene", Sβ+, Sβ°, SE) followed in one of the centers of competence or reference for rare diseases (CRMR) "Major Sickle Cell Syndromes, Thalassemias and Other Rare Pathologies of Red Blood Cell and Erythropoiesis "from Ile de France.
• Patients not subject to legal protection measures.
• Patients affiliated to a French social security scheme
• Informed consent signed

Child-control group:

• Children over 12 months old and under 18 years old at the time of inclusion.
• Children without sickle cell disease
• Children monitored for asthma or with a history of asthma.
• Children not subject to legal protection measures.
• Children affiliated to a French social security scheme
• Informed consent signed by one of the two parents.

Exclusion Criteria:

• Patient group = sickle cell children :
• Infants under 12 months of age.
• Other haemoglobinopathies and heterozygous Haemoglobin AS or AC patients.
• Children already in a treatment protocol or in the exclusion period from a previous investigation.
• Children on state medical assistance

Adult sickle cell group :

• Other haemoglobinopathies and heterozygous AS or AC patients.
• Patients already on a treatment protocol or in the exclusion period from a previous investigation.
• Pregnant or lactating women.
• Patients on state medical assistance

Child control group :

• Infants under 12 months of age and adults over 18 years of age.
• Children already in a treatment protocol or in the exclusion period from a previous study.
• Children on state medical assistance